Clinical Trial

A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \<18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Status change: Not Yet Recruiting → Recruiting 2026-01-07
Trial Details
NCT Number NCT07255209
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Adolescents With Obesity or Overweight With Weight-Related Comorbidities
Enrollment 180 participants
Start Date 2025-12-29
Primary Completion 2027-10-31 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-08